Managing the Cost of C.Difficile Infection: Are You Spending More Than You Know?

• Release Date: December 31, 2020
• Expiration Date: June 30, 2022
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

A.Krishna Rao, MD, MS Assistant Professor Division of Infectious Disease Department of Internal Medicine University of Michigan Medical School Click here for biography Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC Click here for biography James T. Kenney, RPh, MBA Founder and President JTKenney, LLC Click here for biography

Target Audience

• This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview 
The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000.

A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations. In addition, the faculty panel, including managed care experts, will review guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.

Educational Objectives 
After completing this activity, the participant should be better able to: 

1. Review the epidemiology and prevalence of CDI
2. Evaluate novel treatment options for primary and recurrent CDI
3. Apply guideline-based management strategies for CDI
4. Illustrate avoidable costs related to CDI treatment management that can impact benefit design and coverage decision-making

ACCREDITATION

Physician Continuing Medical Education
Accreditation Statement 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates these enduring materials for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Pharmacist Continuing Education

Accreditation Statement  Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Credit Designation
Medical Education Resources designates these continuing education activities for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.
UAN: 0816-9999-20-172-H01-P

This activity is certified as Knowledge-based CPE.

Nursing Continuing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Medical Education Resources is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation
These educational activities for 1.0 contact hour are provided by Medical Education Resources.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF CONFLICTS OF INTEREST

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Merck & Co., Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 31, 2020 through June 30, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet